respiratory failure
Conditions
Interventions
Experimental group:Remazolam toluenesulfonate was injected intravenously to sedation
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 18 years old, gender unlimited; 2.ECMO treatment is required in ICU; 3. 18 kg/m^2 <=BMI<= 30 kg/m^2; 4. Clearly understand and voluntarily participate in this study.
Exclusion criteria
Exclusion criteria: 1.Patients who are expected to die within 48 hours; 2.Previous history of brain injury; 3. The condition requires deep sedation or does not require continuous sedation; 4. Alzheimer's disease; 5. Patients with advanced malignant tumors; 6. palliative care providers; 7. History of alcohol abuse or drug abuse; 8. Patients with severe hepatic and renal insufficiency (creatinine higher than 2mg/l, liver enzymes increased more than 4 times or jaundice); 9. Patients with recent seizures (within 3 months); 10. People who have serious listening difficulties and cannot communicate; 11. Have participated in other clinical trials; 12.Pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the time within the target range of RASS accounts for 70% of the study drug administration time without other rescue treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| the rate of delirium;Proportion of patients treated with sedative medication;The time it takes for consciousness to fully regain after sedation is stopped;Incidence of adverse events;ICU case fatality rate;Dose of sedative and analgesic medication;Duration in the ICU;Total hospitalization costs and sedation and analgesia-related expenses; | — |
Countries
China
Contacts
Public ContactJinyan Xing
The Affiliated Hospital of Qingdao University
Outcome results
None listed